Reporter brief
Dasatinib and quercetin pilot study assessed safety in older adults at Alzheimer's risk.
What happened
This pilot study tested the safety and feasibility of intermittent dasatinib and quercetin dosing in older adults at risk of Alzheimer's disease. The study aimed to evaluate whether the treatment might improve cerebral blood flow, mobility, and cognition. Results of the trial outcomes are not reported in the abstract.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Other; Human.
Older adults at risk of Alzheimer's disease
- Design
- Other
- Sample
- —
- Journal
- Lewis Lipsitz
- Published
- Mar 17, 2025
Effect size
Not recorded.
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Senolytics timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.